Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drug

Trelegy Ellipta(Fluticasone/Umeclidin/Vilanter)GSK plc logoGSK

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by GSK plc

$5.29B

Medicare cost, 2024

Medicare drug plans spent $5.3 billion on Trelegy Ellipta (fluticasone/umeclidin/vilanter) in 2024, for 6.2 million prescriptions and refills filled by 1.3 million patients. It ranks 7th among all drugs by Medicare drug plan spending. Spending rose 19% from 2023 to 2024. Florida accounts for the most spending ($428.0 million, 8% of the total).

Medicare cost, 2024

$5.29B

+18.8% from 2023

Prescriptions

6.2M

$847.00 per claim

Patients

1.3M

237,439 prescribers

Total spending, 2024

$5.29B

$4,172.39 per patient

Questions and answers

How much does Medicare spend on Trelegy Ellipta?

Medicare prescription drug plans paid $5.29B for Trelegy Ellipta in 2024, for 6,248,740 prescriptions and refills to 1,268,461 patients (up 18.8% from 2023). The average cost per claim was $847.00.

Which state spends the most on Trelegy Ellipta?

Florida had the highest Medicare cost for Trelegy Ellipta in 2024: $428.0M for 473,878 claims, followed by New York ($353.5M).

Who prescribes Trelegy Ellipta the most?

Jorge Sanchez-Masiques, pulmonary disease in Miami, FL, had the highest Medicare cost for Trelegy Ellipta in 2024: 3,564 claims costing $2.4M.

Who makes Trelegy Ellipta?

Trelegy Ellipta is made by GSK plc (GSK), listed in the Medicare spending data as Glaxosmithkline.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Trelegy Ellipta was $5.29B in 2024, the highest year shown.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Trelegy Ellipta, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Jorge Sanchez-Masiques Miami, FLPulmonary Disease3,564683$2.4M
Kaiser Toosy New Haven, CTPulmonary Disease2,514466$2.3M
Jason B Karp Lake Success, NYPulmonary Disease1,722533$2.0M
Michael A Imevbore New Haven, CTPulmonary Disease1,541443$1.9M
Ernesto Mejia Morristown, TNPulmonary Disease2,304529$1.8M
Rajesh Agrawal Pinellas Park, FLPulmonary Disease2,210524$1.7M
Ladly Abraham Conway, ARPulmonary Disease2,033389$1.6M
Ahmed S Bhatti Granbury, TXPulmonary Disease2,065434$1.6M
Morgan G Miller Rocky Mount, NCNurse Practitioner1,775385$1.6M
Elizabeth M Kluka Kalamazoo, MICritical Care (Intensivists)2,139383$1.6M
Ashesh D Desai Conroe, TXPulmonary Disease1,298369$1.5M
Rafael A Martinez Tampa, FLPulmonary Disease2,001448$1.5M
Fernando L Martinez Catinchi Hialeah, FLPulmonary Disease2,264708$1.5M
Ajay D Deshpande Terre Haute, INPulmonary Disease1,736404$1.4M
Hoang T Le Fountain Valley, CAPulmonary Disease1,648283$1.4M
Richard A Miller Newark, NJPulmonary Disease1,874359$1.4M
Lohaliz Bobe Port Charlotte, FLPulmonary Disease1,405312$1.4M
Walid F Tanyous Venice, FLPulmonary Disease979340$1.3M
Gary R Schafer Forest City, NCPulmonary Disease1,703314$1.3M
Ahmad M Ibrahimbacha Cleveland, TNPulmonary Disease1,836330$1.3M
Alec J Steils Waterloo, IANurse Practitioner1,456310$1.3M
Stephen G Basheda Pittsburgh, PAPulmonary Disease1,833312$1.3M
Gaurav Sangwan Springfield, ILPulmonary Disease1,618267$1.3M
Rohit G Patel Anniston, ALPulmonary Disease1,766325$1.3M
Wendi Shaffmaster Richmond, INNurse Practitioner1,531289$1.3M

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022175,2143,925,466833,805$3.34B
2023208,0995,007,6131,049,967$4.45B
2024237,4396,248,7401,268,461$5.29B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
GlaxosmithklineGSK logoGSK6,250,872$5.29B

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube